Direct Complete Versus Staged Complete Revascularization in Patients Presenting With Acute Coronary Syndromes and Multivessel Disease

NAActive, not recruitingINTERVENTIONAL
Enrollment

1,525

Participants

Timeline

Start Date

June 22, 2018

Primary Completion Date

October 31, 2022

Study Completion Date

October 31, 2026

Conditions
Acute Coronary Syndrome
Interventions
DEVICE

Percutaneous coronary intervention

At the index procedure, the culprit lesion (cause of complaints/acute coronary syndrome) will be treated according to standard of care with a Biotronik Orsiro DES (Sirolimus-Eluting stent). If there are additional significant lesions besides the culprit lesion, patients will be randomized to direct complete revascularization or staged complete revascularization. In the direct complete revascularization group all lesions will be treated during the index procedure. In the staged complete revascularization group, only the culprit lesion will be treated during the index procedure. The remaining significant lesions will be treated later but within six weeks after the index procedure. In both arms the additional lesions will also be treated with Biotronik Orsiro DES (Sirolimus-Eluting stent).

Trial Locations (1)

3015 GD

Erasmus Medical Center, Rotterdam

Sponsors
All Listed Sponsors
collaborator

Biotronik SE & Co. KG

INDUSTRY

lead

Erasmus Medical Center

OTHER

NCT03621501 - Direct Complete Versus Staged Complete Revascularization in Patients Presenting With Acute Coronary Syndromes and Multivessel Disease | Biotech Hunter | Biotech Hunter